Mirum Pharmaceuticals, Inc. Common Stock (MIRM) Financials
Key financial figures for Mirum Pharmaceuticals, Inc. Common Stock (Q2 2026).
Mirum Pharmaceuticals, Inc. reported revenue of $176.2 million for Q2 FY2026, up 37.9% from the same period a year earlier. The company posted a net loss of $67.2 million, or -$1.06 per share. Operating margin came to -24.14%, against -3.9% a year earlier. Free cash flow for the period was -$273.7 million. Across the last 5 reported quarters, quarterly revenue has risen from $127.8 million in Q2 FY2025 to $176.2 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Mirum Pharmaceuticals, Inc. are on the SentiSense financials page.
- Revenue
- $176M
- Net Income
- -$67M
- EPS
- $-1.06
- Total Assets
- $1.0B
- Operating Cash Flow
- -$44M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $176M | -$67M | -$1.06 | -24.14% | -$274M |
| Q1 FY2026 | $160M | -$790M | -$13.43 | -39.51% | -$229M |
| Q4 FY2025 | $149M | -$6M | -$0.12 | -3.07% | $5M |
| Q3 FY2025 | $133M | $3M | $0.05 | 1.96% | $39M |
| Q2 FY2025 | $128M | -$6M | -$0.12 | -3.9% | $12M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $521M | -$23M | -$0.47 | -4.25% | $55M |
| FY2024 | $337M | -$88M | -$1.85 | -26% | $9M |
| FY2023 | $186M | -$163M | -$4.00 | -58.57% | -$91M |
Frequently asked questions
What was Mirum Pharmaceuticals, Inc.'s revenue last quarter?
Mirum Pharmaceuticals, Inc. reported revenue of $176.2 million for Q2 FY2026, up 37.9% from the same period a year earlier.
Is Mirum Pharmaceuticals, Inc. profitable?
Not in its most recent reported period. Mirum Pharmaceuticals, Inc. reported a net loss of $67.2 million for Q2 FY2026, a net margin of -38.14% on revenue.
How has Mirum Pharmaceuticals, Inc.'s margin trended?
Operating margin was -24.14% in Q2 FY2026, compared with -3.9% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Mirum Pharmaceuticals, Inc. generate?
Mirum Pharmaceuticals, Inc. generated free cash flow of -$273.7 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Mirum Pharmaceuticals, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.